about
A multicenter phase II study of sepantronium bromide (YM155) plus rituximab in patients with relapsed aggressive B-cell Non-Hodgkin lymphoma.Preclinical efficacy of sepantronium bromide (YM155) in multiple myeloma is conferred by down regulation of Mcl-1.A phase 2, multicenter, open-label study of sepantronium bromide (YM155) plus docetaxel in patients with stage III (unresectable) or stage IV melanomaPharmacokinetics of sepantronium bromide (YM155), a small-molecule suppressor of survivin, in Japanese patients with advanced solid tumors: dose proportionality and influence of renal impairment.YM155, a survivin suppressant, triggers PARP-dependent cell death (parthanatos) and inhibits esophageal squamous-cell carcinoma xenografts in miceA combination of YM-155, a small molecule survivin inhibitor, and IL-2 potently suppresses renal cell carcinoma in murine model.Population pharmacokinetic modeling of sepantronium bromide (YM155), a small molecule survivin suppressant, in patients with non-small cell lung cancer, hormone refractory prostate cancer, or unresectable stage III or IV melanoma.YM-155 potentiates the effect of ABT-737 in malignant human glioma cells via survivin and Mcl-1 downregulation in an EGFR-dependent context.Survivin inhibitor YM-155 sensitizes tumor necrosis factor- related apoptosis-inducing ligand-resistant glioma cells to apoptosis through Mcl-1 downregulation and by engaging the mitochondrial death pathwayA phase I/II study of sepantronium bromide (YM155, survivin suppressor) with paclitaxel and carboplatin in patients with advanced non-small-cell lung cancer.Rapamycin enhances the anti-angiogenesis and anti-proliferation ability of YM155 in oral squamous cell carcinoma.YM155 suppresses cell proliferation and induces cell death in human adult T-cell leukemia/lymphoma cells.Antitumor activity of YM155, a selective survivin suppressant, in combination with cisplatin in hepatoblastoma.Formulation design and evaluation of liposomal sepantronium bromide (YM155), a small-molecule survivin suppressant, based on pharmacokinetic modeling and simulation.Antitumor efficacy and biodistribution of liposomal sepantronium bromide (YM155), a novel small-molecule survivin suppressant.Synergistic antitumor activities of sepantronium bromide (YM155), a survivin suppressant, in combination with microtubule-targeting agents in triple-negative breast cancer cells.Therapeutic potential of sepantronium bromide YM155 in gemcitabine-resistant human urothelial carcinoma cells.Sepantronium bromide (YM155) induces disruption of the ILF3/p54(nrb) complex, which is required for survivin expression.Sepantronium bromide (YM155) enhances response of human B-cell non-Hodgkin lymphoma to rituximab.Mathematical Modeling of the Role of Survivin on Dedifferentiation and Radioresistance in Cancer.Targeting survivin with YM155 (Sepantronium Bromide): a novel therapeutic strategy for paediatric acute myeloid leukaemia.Sepantronium bromide (YM155) improves daratumumab-mediated cellular lysis of multiple myeloma cells by abrogation of bone marrow stromal cell-induced resistance.Lack of differences in the pharmacokinetics of sepantronium bromide (YM155) between US and Japanese patients with advanced solid tumors or non-Hodgkin lymphoma.YM155 inhibits topoisomerase function.Liquid chromatography-tandem mass spectrometric assay for the light sensitive survivin suppressant sepantronium bromide (YM155) in mouse plasma
P921
Q33429865-FE5E58D7-20B0-40F5-A9C2-A1F6D5627663Q34786411-912A3E38-EF5E-4AD3-9E72-A25E2ABE5454Q35602111-74B8B68F-085F-4CAD-A6FB-7E7E35FEFFDDQ36192077-8DFB0F23-AB9A-4AEC-8279-28032715460AQ36210899-9EDFA8BF-CC68-4BFC-AEB6-C5D41D46CA6FQ36356265-6DAD1678-5636-4BAF-9ADA-699D812B8C9BQ36660459-87E049FA-5ECD-4932-8910-F4B3C5078B61Q36681060-CBFB8C1D-36AE-4267-B7A4-3A583D59908AQ37027010-A0A9C13B-982A-4A77-B4F0-F5931BEC7F6AQ37200511-A735D49A-8C8E-4FCB-9481-2BF0828C1E95Q38700218-74C2F4CB-74FF-4459-93B2-3B83F3AB7CCFQ38821241-328DCB79-5F0A-4092-9E79-464AD04738CEQ38877619-3FDB701C-0F6D-411E-9143-285376657A93Q38974596-064120F7-83FB-4266-B05F-1EDA35A16352Q38978254-F77AF196-EBD2-4611-9943-7F7E68515FFCQ39033975-9C85B0E9-4C16-4A56-B90B-1AEC3A9684EDQ39050756-136924F7-3C7B-4634-ADC2-48DB35450D80Q39306813-A9C4F622-2D61-4AFB-A93D-07BDC7B5C0D5Q39316157-DDA55553-F8CF-4F9B-ADD5-34F9D0DCE8EBQ39704104-96CB9B94-2452-474C-9B98-021154F17F1DQ41467756-A6628CB4-829F-4062-BDB1-23B079DDD471Q42391580-B4586E7F-C8DA-4020-8492-3F165EF49AE7Q44573754-2E671ADE-0488-43E8-8F73-CB0FFCB4873FQ49218909-24FB4393-1E2D-4941-B5A5-DB36A5CE8750Q87273463-EC9A4503-5DBC-445A-BC59-347591BC2ABC
P921
description
chemesch Verbindung
@lb
chemical compound
@en
chemical compound
@en-ca
chemical compound
@en-gb
chemická sloučenina
@cs
chemická zlúčenina
@sk
chemiese verbinding
@af
chemische Verbindung
@de
chemische Verbindung
@de-ch
chemische verbinding
@nl
name
sepantronium bromide
@en
type
label
sepantronium bromide
@en
prefLabel
sepantronium bromide
@en
P592
P661
P662
P683
P2067
P231
781661-94-7
P233
CC1=[N+](C2=C(N1CCOC)C(=O)C3=CC=CC=C3C2=O)CC4=NC=CN=C4.[Br-]
P234
1S/C20H19N4O3.BrH/c1-13-23(9-1 ...... 1H,9-10,12H2,1-2H3;1H/q+1;/p-1
P235
QBIYUDDJPRGKNJ-UHFFFAOYSA-M
P274
C₂₀H₁₉BrN₄O₃
P3117
DTXSID90228817
P592
CHEMBL2105734
P652
7H5Q4J1CM5